Cargando…

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab

Primary melanocytic tumors of the CNS are extremely rare conditions, encompassing different disease processes including meningeal melanoma and meningeal melanocytosis. Its incidence range between 3-5%, with approximately 0.005 cases per 100,000 people. Tumor biological behavior is commonly aggressiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burgos, Remberto, Cardona, Andrés F., Santoyo, Nicolas, Ruiz-Patiño, Alejandro, Cure-Casilimas, Juanita, Rojas, Leonardo, Ricaurte, Luisa, Muñoz, Álvaro, Garcia-Robledo, Juan Esteban, Ordoñez, Camila, Sotelo, Carolina, Rodríguez, July, Zatarain-Barrón, Zyanya Lucia, Pineda, Diego, Arrieta, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766339/ https://www.ncbi.nlm.nih.gov/pubmed/35070950 http://dx.doi.org/10.3389/fonc.2021.691017

Ejemplares similares

Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab − Diagnostic and Therapeutic Challenge: A Case Report
por: Cardona, Andrés F., et al.
Publicado: (2020)

Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies
por: Sotelo-Rodríguez, Diana Carolina, et al.
Publicado: (2019)

When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
por: Rodríguez, July, et al.
Publicado: (2021)

Comprehensive review of fetal adenocarcinoma of the lung
por: Ricaurte, Luisa María, et al.
Publicado: (2018)

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
por: Cardona, Andrés F., et al.
Publicado: (2021)

Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2020)

Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado
por: Cañas, Alejandro, et al.
Publicado: (2022)

Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2020)

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2021)

Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
por: Cardona, Andrés F., et al.
Publicado: (2020)

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2019)

Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2020)

Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
por: Cardona, Andrés F., et al.
Publicado: (2019)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP‐LATimus)
por: Martín, Claudio, et al.
Publicado: (2021)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
por: Takamatsu, Dai, et al.
Publicado: (2019)

Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer
por: Rolfo, Christian, et al.
Publicado: (2020)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
por: Raez, Luis E., et al.
Publicado: (2022)

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy
por: Barrón, Feliciano, et al.
Publicado: (2020)

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2019)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fit30khd8kkpuppho3js2fee1q